Primary progressive MS

Giovannoni. Primary progressive MS. ACNR 2012;12(3):9-12.


Although PPMS is relatively uncommon it remains a significant clinical problem both diagnostically and therapeutically. PPMS is almost certainly part of the MS spectrum and there is no clinicopathological evidence to support PPMS as being a separate disease. Unfortunately, there are no licensed DMTs that have been shown to modify the course of PPMS. Despite this there is some emerging evidence that PPMS may respond to immunomodulatory therapies. Two large phase 3 trials are currently underway to test this hypothesis.


"This is a short review on PPMS; you may be interested in the section on diagnostic criteria."


CoI: This mini-review was written by myself and we are a trial site for both the fingolimod and ocrelizumab PPMS trials, sponsored by Novartis and Roche, respectively.

Labels: , , ,